Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441745-B2 | Processes and compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | claimed |
| CN-120081864-A | Synthesis method of 1, 3-diboron compound | 西安交通大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119569588-A | Preparation method and intermediate of ilast hydrochloride | 杭州诺澳生物医药科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-113348163-B | Methods and compounds | 雷迪厄斯制药公司 | 2024-10-08 | — | — | CN | claimed |
| CN-117964513-B | Specific functional compound and preparation method and application thereof | 广州伽能生物科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-117964513-A | Specific functional compound and preparation method and application thereof | 广州伽能生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-114853628-B | Docosahexaenoic acid acyl ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2023-10-13 | — | — | CN | claimed |
| CN-116535280-A | Synthesis method of alkynyl thioether compound | 江南大学 | 2023-08-04 | — | — | CN | claimed |
| CN-114853628-A | Docosahexaenoic acid ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | claimed |
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| CN-120117987-A | Arylalkanoic acid phloroglucinol ester compound, preparation method and application thereof | 南华大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-120081864-A | Synthesis method of 1, 3-diboron compound | 西安交通大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-119569588-A | Preparation method and intermediate of ilast hydrochloride | 杭州诺澳生物医药科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119390714-A | Methods and compounds | 雷迪厄斯制药公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-116535280-A | Synthesis method of alkynyl thioether compound | 江南大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023134733-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023086696-A2 | APPARATUS AND METHODS FOR CONTINUOUS FLOW SYNTHESIS OF CISATRACURIUM | ODH IP Corp. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-115838338-A | Method for preparing amide | 浙江工业大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114853628-A | Docosahexaenoic acid ester derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022101408-A1 | SYNTHESIS OF HYDROMORPHONE BASE | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441745-B2 | Processes and compounds | ESR1, ESR2, CYP19A1 | PTGS2 2673/4885PTGS1 1214/4885AKR1C3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.